Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming by Gonçalves, Eduardo DC et al.
  Universidade de São Paulo
 
2007-08
 
Improve protective efficacy of a TB DNA-
HSP65 vaccine by BCG priming
 
 
 
http://www.producao.usp.br/handle/BDPI/33032
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Patologia e Medicina Legal - FMRP/RPM Comunicações em Eventos - FMRP/RPM
BioMed Central
Page 1 of 14
(page number not for citation purposes)
Genetic Vaccines and Therapy
Open AccessResearch
Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG 
priming
Eduardo DC Gonçalves1, Vânia Luiza D Bonato1, Denise M da Fonseca1, 
Edson G Soares3, Izaíra T Brandão2, Ana Paula M Soares2 and Célio L Silva*1
Address: 1Farmacore Biotecnologia Ltda, Rua dos Técnicos s/n, Campus da USP, Ribeirão Preto, SP, Brazil, 2Center for Tuberculosis Research, 
Department of Biochemistry and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil and 3Department of 
Pathology, School of Medicine of Ribeirão Preto, University of São Paulo, Brazil
Email: Eduardo DC Gonçalves - eduardo@farmacore.com.br; Vânia Luiza D Bonato - vlbonato@fmrp.usp.br; Denise M da 
Fonseca - denise@cpt.fmrp.usp.br; Edson G Soares - egsoares@fmrp.usp.br; Izaíra T Brandão - izausp@cpt.fmrp.usp.br; Ana Paula 
M Soares - masson@fmrp.usp.br; Célio L Silva* - clsilva@fmrp.usp.br
* Corresponding author    
Abstract
Vaccines are considered by many to be one of the most successful medical interventions against
infectious diseases. But many significant obstacles remain, such as optimizing DNA vaccines for use
in humans or large animals. The amount of doses, route and easiness of administration are also
important points to consider in the design of new DNA vaccines. Heterologous prime-boost
regimens probably represent the best hope for an improved DNA vaccine strategy. In this study,
we have shown that heterologous prime-boost vaccination against tuberculosis (TB) using
intranasal BCG priming/DNA-HSP65 boosting (BCGin/DNA) provided significantly greater
protection than that afforded by a single subcutaneous or intranasal dose of BCG. In addition,
BCGin/DNA immunization was also more efficient in controlling bacterial loads than were the
other prime-boost schedules evaluated or three doses of DNA-HSP65 as a naked DNA. The single
dose of DNA-HSP65 booster enhanced the immunogenicity of a single subcutaneous BCG
vaccination, as evidenced by the significantly higher serum levels of anti-Hsp65 IgG2a Th1-induced
antibodies, as well as by the significantly greater production of IFN-γ by antigen-specific spleen cells.
The BCG prime/DNA-HSP65 booster was also associated with better preservation of lung
parenchyma.
The improvement of the protective effect of BCG vaccine mediated by a DNA-HSP65 booster
suggests that our strategy may hold promise as a safe and effective vaccine against TB.
Background
Tuberculosis (TB) remains a leading cause of infectious
disease mortality worldwide, accounting for nearly 2 mil-
lion deaths annually. Despite the availability of effective
anti-TB therapy, the world's case burden of TB continues
to climb, in part owing to the concurrent acquired
immune deficiency syndrome pandemic. The widespread
use of the current TB vaccine, M. bovis bacillus Calmette-
Guérin (BCG), has failed to curtail the TB epidemic.
Therefore, TB eradication will require the development of
an improved vaccine, which, in turn, will require applica-
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tion of state-of-the-art vaccine technology and new strate-
gies.
A new vaccine against TB would need to induce protection
superior to that elicited by the BCG vaccine and to permit
administration to healthy individuals, infected individu-
als and perhaps even individuals presenting the active
form of the disease. Thus, various strategies have been
employed for the development and evaluation of new TB
vaccines. Recombinant BCG strains, DNA-based vaccines,
live attenuated Mycobacterium tuberculosis vaccines and
subunit vaccines formulated with novel adjuvants have
shown promise in preclinical animal models [1]. The abil-
ity of DNA vaccines to elicit Th1-biased CD4+ responses
and strong cytotoxic T lymphocyte responses make them
particularly attractive as weapons against M. tuberculosis
infection.
Experimental data collected by our group over the last few
years have shown that a DNA vaccine encoding the M. lep-
rae 65-kDa heat shock protein (DNA-HSP65) has prophy-
lactic and therapeutic effects in a murine model of TB [2-
5]. The prophylactic effect initially obtained from this vac-
cine was equal to that elicited by BCG vaccine [3,6]. How-
ever, we would like to optimize this DNA vaccine for use
in humans, and the prime-boost strategy seems a very
promising option.
Heterologous prime-boost strategy has shown promise in
various models of pathogenic infections [7]. The results
have been highly encouraging both in augmenting and
modulating vaccine-induced immunity. This strategy is
based on the combination of live attenuated viruses or
BCG with DNA vaccines or recombinant proteins [8]. In
experimental models of TB, the ability of prime-boost
strategy to complement the protection provided by BCG
vaccination has been assayed [9]. Such studies have
shown that DNA-prime that codifying M. tuberculosis
genes (Apa, HSP65 and HSP70), BCG-booster induced a
higher level of protection than BCG alone [10]. However,
boosting the BCG vaccine with a recombinant modified
vaccinia virus Ankara (MVA) expressing M. tuberculosis
85A antigen also induced higher levels of antigen-specific
CD4+ and CD8+ T cells and greater protection against aer-
osol challenge [11]. Others have demonstrated that BCG-
prime DNA-Rv3407 (M. tuberculosis 10 kDa protein)-
booster induced a greater protection against TB than BCG
alone [12]. In the present study, we investigated the influ-
ence that the order and route of BCG vaccination in com-
bination with DNA-HSP65 vaccine has on the induction
of protective immunity against TB.
Methods
Mice
SPF female BALB/c mice, 6–8 weeks old, were purchased
from the University of São Paulo – FMRP. All mice were
kept under specific pathogen-free conditions in a BSL 3
facility. All animal studies were conducted in accordance
with the Institutional Animal Care and Ethics Rules of
University of São Paulo – Brazil.
Bacteria
The M. tuberculosis H37Rv (n° 27294; ATCC, Rockville,
MD, USA) and M. bovis BCG (Pasteur strain) were grown
in an incubator for 7 days at 37°C in 7H9 Middlebrook
broth (Difco, USA) enriched with 0.2% (v/v) glycerol and
10% (v/v) OADC (Difco, USA) and was prepared as
described [5].
Plasmid construction
The DNA vaccine pVAX-hsp65 (DNA-HSP65) was derived
from the pVAX vector (Invitrogen, Carlsbad, CA, USA)
and was constructed as described [13]. Endotoxin levels
were measured using the Limulus amebocyte lysate kit –
QCL-1000 (BioWhittaker, Walkersville, MD, USA). Endo-
toxin levels for plasmid used in this study were ≤ 0.1
endotoxin units/µg of DNA.
Immunization and challenge infection
Groups of mice were separated by immunization schedule
as shown in Table 1. For DNA vaccination, a single 50-µg
dose of DNA-hsp65 in 50 µL of saline plus 50% sucrose
was injected into each quadriceps muscle 3 times in a 15
day-intervals by using insulin syringe with an ultra-fine II
short needle (Becton and Dickson, Franklin Lakes, NJ –
USA). For intranasal (i.n.) delivery of BCG, animal groups
were lightly anesthetized with tribromoethanol 2,5%
(Across Organics) and 105 bacilli in 30 µl of PBS/mouse
was administered dropwise to external nostrils of the mice
(15 µl per nostril) with a fine pipette tip. For subcutane-
ous (s.c.) delivery, animals received 105 bacilli in 100 µl of
PBS/mouse. At 15 or 60 days after the last immunization,
mice were challenged through instillation of bacterial
solution (105 bacteria/animal) by intratracheal route
according to harmonization procedures of animals. For
each route of immunization and challenge an equal quan-
tity of PBS was administered to the controls.
Blood collection and antibody evaluation
Prior to the first immunization (pre-immune serum) and
15 days after the last immunization, individual serum
samples were colleted by retro-orbital sinus puncture.
Antibody levels in samples were measured by enzyme-
linked immunosorbent assay (ELISA) described [13].
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Recombinant M. leprae hsp65
Clone pIL161, containing the DNA coding for the M. lep-
rae HSP65, was transformed into electrocompetent DH5α
Escherichia coli cells. Briefly, DH5α E. coli cells containing
pIL161 were grown in the presence of ampicillin to an
OD600 of 0.6. The expression of the recombinant protein
was induced by the addition of IPTG (isopropril-thi-B-D-
galactosídeo) 0.5 mM. The induced culture was incubated
for another 4 h at 30°C and was harvested by centrifuga-
tion (5000 g, 5 min, 4°C), then the pellet was lysed by
sonication at 60 Hz with two cycles of 60 s (Tomy-Seiko,
Japan). After washed with 10 mL of CE buffer, the pellet
was resuspended in 5 mL of UPE buffer and the suspen-
sion was gently shaken at room temperature for 15 min.
The insoluble material was washed by centrifugation at
10000 g for 20 min, a 3.6 M ammonium sulfate stock
solution was added followed by incubation on ice for 30
min. This fraction was dissolved in 50 mM phosphate
buffer to produce the crude fraction. The recombinant M.
leprae Hsp65 was first fractionated on a FPLC-GP-250 Plus
system (MonoQ HR 5/5, Pharmacia Biotech) using 50
mM phosphate buffer and eluted with a 20–600 mM
NaCl gradient under a flow rate of 1 mL/min. Subse-
quently, the protein solution (100 µg) was resolved on a
HPLC system (Shimadzu Class VP) and recombinant M.
leprae Hsp65 was collected and the homogeneity of the
recombinant M. leprae Hsp65 preparations was analyzed
by polyacrylamide gel electrophoresis. Protein concentra-
tions and endotoxin levels were determined as previously
described [5,14].
Cytokine detection
The levels of IFN-γ, interleukin (IL)-12, IL-10, TNF-α, IL-4
and IL-5 in the spleen cell supernatants and in lung
homogenates from immunized mice were measured by
ELISA as previously described [5]. The following capture
antibody anti-mouse IFN-γ, IL-12, IL-10, TNF-α, IL-4 or
IL-5 (R46A2, 15.6, JES5-2A4, mIL4R-M2 and TRFK5
clones, respectively; Pharmingen) were used. Cytokine-
antibody complexes were detected by the addition of
biotin anti-mouse IFN-γ, IL-12, IL-10, TNF-α, IL-4 or IL-5
(XMG1.2, C17.8, SXC-1, B11-3 and TRFK4 clones, respec-
tively; PharMingen). Detection limits were 40 pg/mL (for
IFN-γ and 10 pg/mL (for IL-12 and IL-10, TNF-α, IL-4 and
IL-5).
Elispot Assay
The ELISPOT method was used to detect IFN-γ secretion
by spleen cells from immunized mice. In brief, ELISPOT
plates (BD Biosciences) were coated with capture IFN-γ
antibody overnight at 4°C. After washed and blocked
with complete medium, the plates were incubated for 2 h
at room temperature. The spleen was removed from each
mouse aseptically. Red blood cells were removed from the
spleen cells preparations using red blood cell lysis buffer
(NH4Cl 0,16 M/Tris 0,17 M/pH 7,65). Cells were placed
in RPMI-C 1640 medium (R-6504 – Sigma, St. Louis,
USA) supplemented with 100 U/mL penicillin, 100 µg/
mL streptomycin, and 10% of fetal bovine serum (all from
Gibco-BRL). The cells were incubated (2 × 106 cells/well)
for 48 h at 37°C with 5% CO2, with medium, concanava-
lin-A (20 µg/well) or recombinant Hsp65 (10 µg/well)
and then were discarded. Plates were washed with de-ion-
ized water and PBS/Tween 20. Secondary biotinylated
antibody was added for 2 h and incubated at room tem-
perature, followed by washing with PBS/Tween 20.
Streptavidin-alkaline phosphatase was added to the plates
for 1 h, followed by washing and by the development of a
colour reaction using the AEC substrate reagent kit (BD
Biosciences). The reaction was stopped by rinsing the
plate with running water. The spots were enumerated
using an ELISPOT reader (Biosys – Germany).
Protection assay
Thirty days after challenge, aliquots of lungs harvested
from infected, sham-immunized mice and from immu-
nized, infected mice were incubated in digestion solution
as described [5]. Serial 10-fold dilutions were plated on
supplemented 7H11 agar media (Difco, USA). Colonies
were counted after 28 days of incubation at 37°C with 5%
CO2, and the results were expressed as CFU (g/lung).
Preparation of lung cells
Lungs were washed with sterile PBS and were placed in
Petri dishes containing incomplete RPMI-1640 (R-6504 –
Sigma, St. Louis, USA). Then, they were fragmented and
transferred to conical tubes containing 0.5 µg/mL of Lib-
erase Blendzyme 2 (Roche, Indianapolis, IN, USA) in
incomplete RPMI-1640. Samples were processed as previ-
ously described [5].
Table 1: Heterologous prime-boost regimen combinations
GROUP PRIME BOOSTERa
PBS PBS PBS
BCGsc Subcutaneousb BCG -
BCGin Intranasalc BCG -
BCGin/DNA Intranasal BCG Intramusculard DNA-
hsp65
BCGsc/DNA Subcutaneous BCG Intramuscular DNA-
hsp65
DNA-hsp65 3 doses of 
intramusculard
DNA-hsp65 – 15 days of 
interval
aInterval between prime and booster: 15 days
bSubcutaneous route: 105 bacteria in 30 microliters
cIntranasal route: 105 bacteria in 100 microliters
dIntramuscular route: 100 micrograms in 100 microliters/dose, 3 
doses at 15-day intervals
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Fluorescence-activated cell sorter analysis
To evaluate T cell subsets, effector function and memory
markers, the following mAbs and their respective isotype
controls were used: anti-CD62L (clone MEL-14), anti-
CD4 (clones H129.19 and RM4-5), anti-CD8 (clone 53-
6.7), anti-CD44 (clone Ly-24); rat-IgG2a-fluorescein iso-
thiocyanate, rat-IgG2a-phycoerythrin and rat-IgG2a-
peridinin chlorophyll protein. All mAbs were purchased
from Pharmingen and used according to the manufacturer
instructions. Lymphocytes were analyzed by flow cytome-
try using the CellQuest software FACSort (Becton Dickin-
son, San Jose, CA). Ten thousand events per sample were
collected, and three-color fluorescence-activated cell
sorter analysis was performed. Expression of CD62Llo and
CD44hi was performed by dot plot in CD4+ or CD8+ gated
lymphocyte populations.
Histology
Lung samples were fixed in 10% buffered formalin. Five-
micrometer sections were stained with hematoxylin-eosin
and the granulomatous lesions were analyzed by light
microscopy (Leica, Germany).
Statistical analysis
All data were analyzed individually and the values were
expressed as mean ± SEM. When the values indicated the
presence of a significant difference by analysis of variance
(ANOVA), a Tukey-Kramer multiple comparisons test was
used. Values of P <0.05 were considered significant.
Results
DNA-HSP65 boosting of BCGin provides greater 
protection than other immunization strategies
Initially, we tested the ability of different combinations of
prime-boost strategies to induce protection against M.
tuberculosis and compared the results with those obtained
using classical BCG vaccination or naked DNA-HSP65
immunization through the detection of the number of
colony-forming units (CFU). Significant protection
against experimental TB was achieved in all immunized,
infected mice using the various prime-boost strategies
(Table 1) or three DNA-HSP65 homologous immuniza-
tions or a single BCG dose (BCGin or BCGsc) (Fig. 1A).
However, BCGin/DNA immunized, infected mice pre-
sented a reduction of 3,1 LOG10 in the lung, a significantly
greater degree in relation to non-immunized, infected
group (Fig. 1A). The other immunized, infected mice also
presented a significant reduction, as follows: BCGsc (1,49
LOG10), BCGin (1,94 LOG10), DNA-hsp65 (2,1 LOG10),
BCGsc/DNA (2,14 LOG10). DNA prime/BCG booster also
induced significant protection in relation to non-immu-
nized, infected group (data not shown). Additionally,
when compared with BCGsc (1,63 LOG10), BCGin (1,16
LOG10) and DNA-HSP65 (1,0 LOG10), the BCGin/DNA
group presented a significant reduction of bacterial load
Prime-boost strategy-induced protection against M. tuberculosis challengeFigure 1
Prime-boost strategy-induced protection against M. tuberculosis challenge. 
Groups of 7 BALB/c mice were immunized as shown in Table 1. Control 
mice received PBS prior to infection (infected group). (A) Fifteen days 
after the last immunization, the mice were challenged with M. tuberculosis. 
Thirty days later, the number of live bacteria in the lungs was determined 
and expressed as CFU/lung. (B, C) Sixty days after the last immunization, 
the mice were challenged and 30 (B) and 70 (C) days later, the number of 
CFU was determined. Bars represent the mean ± standard deviation. (A) 
 all immunized-infected mice vs infected mice. * BCGin/DNA vs BCGsc, 
BCGin, DNA-HSP65 and BCGsc/DNA. (B)  BCGin/DNA, DNA-HSP65 
and BCGin vs infected mice. * BCGin/DNA vs BCGsc, BCGin and DNA-
HSP65. (C)  BCGin, DNA-HSP65 and BCGin/DNA vs infected mice. * 
BCGin/DNA vs BCGsc and DNA-HSP65. p < 0.05 was considered signifi-
cant. Data are representative of two experiments.
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(Fig. 1A). In another set of experiments, the challenge was
performed 60 days after the last immunization and 30 or
70 days post-infection the CFU burden recovered from
lungs was determined (Fig. 1B and 1C), respectively. We
verified 30 days post-infection that all immunized,
infected groups presented significant reduction of CFU in
the lung when compared with infected group (Fig. 1B).
Moreover, only BCGin/DNA group presented significant
reduction of CFU compared with the other groups: BCGin
(0,62 LOG10), BCGsc (0,67 LOG10) and DNA-HSP65
(0,84 LOG10) (Fig. 1B). When the bacterial burden was
determined by CFU analysis 70 days post-infection, a sig-
nificant reduction of burden was observed in BCGin,
DNA-HSP65 and BCGin/DNA groups (1,22 LOG10, 1,05
LOG10 and 1,75 LOG10, respectively) compared with
infected group (Fig. 1C). In addition, BCGin/DNA group
also presented a significant reduction in the number of
CFU when compared with BCGin (0,53 LOG10) and
DNA-HSP65 (0,74 LOG10) groups (Fig. 1C).
BCGin/DNA induces enhanced humoral immune response
In order to evaluate the humoral immune response in
serum from all immunized mice and control group (PBS-
injected group) the serum was collected before (pre-
immune) and 15 days after the last immunization. We
verified that all immunized mice presented significant lev-
els of anti-Hsp65 IgG2a after 15 days of the last immuni-
zation (Fig. 2A). Moreover, BCGin/DNA immunized-
mice produced significant levels of IgG2a, (1,41 LOG10)
in relation to mice immunized with a single dose of
BCGin (1,06 LOG10) or BCGsc (0,86 LOG10) and a
homologous DNA-HSP65 immunization (1,0 LOG10)
(Fig. 2A). No significant differences were found among
specific IgG1 antibody levels collected post-immuniza-
tions in relation to PBS group (data not shown).
BCGin/DNA stimulates a Th1 immune response
To evaluate the specific cytokine production from spleen
cell cultures of non-immunized and immunized-mice 15
days after the last immunization, the ELISA assay was per-
formed. After specific stimulation with rHsp65, the spleen
cells of all immunized-mice, BCGsc (2275 ± 807 pg/mL),
BCGin (3256 ± 120 pg/mL), DNA-HSP65 (3139 ± 383
pg/mL), BCGsc/DNA (2931 ± 430 pg/mL), produced sig-
nificant levels of IFN-γ in relation to PBS group (Fig. 2B).
However, the spleen cells of BCGin/DNA immunized-
mice produced significantly higher levels of detectable
IFN-γ (4411 ± 799 pg/mL) compared with the levels pro-
vided by other immunized mice (Fig. 2B). A similar pat-
tern of cytokine production was observed in relation to IL-
12, with the exception of BCGsc group that did not pro-
duce significant levels of IL-12 in relation to PBS group
(Fig. 2C). The other groups of immunized-mice produced
different levels of IL-12: BCGin/DNA (5025 ± 747 pg/
mL), BCGsc (2208 ± 1055 pg/mL), BCGin (3803 ± 385
pg/mL), DNA-HSP65 (2962 ± 474 pg/mL) and BCGsc/
DNA (3806 ± 942 pg/mL) (Fig. 2C). On top of that, the
levels of IL-12 produced by BCGin/DNA group were sig-
nificantly higher than those produced by DNA-HSP65
group (Fig. 2C). In addition to identifying the cytokines
IFN-γ and IL-12, which are associated with the Th1 pat-
tern, we found that the BCGin/DNA immunization sched-
ule stimulated significantly higher IL-10 production (627
± 174 pg/mL) compared with that provided by BCGsc
(237 ± 110 pg/mL) and BCGsc/DNA (393 ± 102 pg/mL)
groups (Fig. 2D). Similar levels of IL-10 were produced by
BCGin/DNA, BCGin and DNA-HSP65 groups. Besides,
we verified that DNA-HSP65 (38 ± 7 pg/mL), BCGin/
DNA (59 ± 10 pg/mL) and BCGsc/DNA (59 ± 6 pg/mL)
immunized-mice also produced significant levels of IL-4
compared with PBS group (Fig. 2E). In relation to ELIS-
POT assay, significant number of IFN-γ producing cells
was mainly observed in BCGin/DNA mice (45 spots) in
comparison with the number detected in PBS group and
in the other immunized groups: BCGin, DNA-HSP65,
BCGsc/DNA and BCGin/DNA (Fig. 2F).
Maintenance of Th1-type response after challenge with M. 
tuberculosis
In order to evaluate the profile of immune response after
mycobacterial challenge, the cytokine production in lung
homogenates was analyzed 30 days post-infection. All
immunized, infected mice displayed significant levels of
IFN-γ production: BCGsc (3964 ± 624 pg/mL), BCGin
(4760 ± 488 pg/mL), DNA-HSP65 (4583 ± 394 pg/mL),
BCGin/DNA (6618 ± 806 pg/mL) and BCGsc/DNA (6067
± 902 pg/mL) in relation to infected mice (2103 ± 488 pg/
mL) (Fig. 3A). However, the BCGin/DNA and BCGsc/
DNA immunized, infected mice presented higher levels of
IFN-γ than other groups analyzed (Fig. 3A). Besides,
BCGin/DNA group presented significant production of
IFN-γ compared with BCGsc, BCGin and DNA-HSP65
(Fig. 3A) groups. We also observed that all immunized,
infected mice produced significant levels of IL-12: BCGsc
(3507 ± 541 pg/mL), BCGin (3267 ± 334 pg/mL), DNA-
HSP65 (3120 ± 271 pg/mL), BCGin/DNA (5187 ± 855
pg/mL) and BCGsc/DNA (3158 ± 569 pg/mL) in relation
to infected mice (Fig. 3B). The levels of IL-12 produced in
the lung homogenates from BCGin/DNA immunized,
infected mice were significantly higher than those pro-
duced by BCGin, BCGsc and DNA-HSP65-immunized,
infected mice (Fig. 3B). Analysis of IL-10 revealed that
mice from BCGsc (643 ± 121 pg/mL), BCGin (696 ± 63
pg/mL) and DNA-HSP65 (720 ± 82 pg/mL) groups pro-
duced lower levels of IL-10 in the lungs in comparison
with the levels produced in the homogenates of mice
immunized with the "prime-boost" schedule: BCGin/
DNA (1097 ± 101 pg/mL) and BCGsc/DNA (1036 ± 89
pg/mL) (Fig. 3C). In addition, the levels of IL-10 pro-
duced by BCGin/DNA group were significantly different
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Specific immune response detected in mice immunized or sham-immunized as described in Table 1Figure 2
Specific immune response detected in mice immunized or sham-immunized as described in Table 1. (A) IgG2a specific antibod-
ies detected in serum collected before the first immunization (pre-immune) and 15 days after the last immunization. Detection 
of cytokines in supernatants of spleen cell cultures and IFN-gamma-producing cells (spleen cells) detected by ELISPOT. Groups 
of 7 mice were sacrificed 15 days after the last immunization, and the spleen cells were cultured in medium with or without 
rhsp65 (10 micrograms/well). (B) IFN-gamma, (C) IL-12, (D) IL-10, (E) IL-4 and (F) IFN-gamma spots. Bars represent the mean 
± standard deviation. (A)  all immunized-mice vs Infected. * BCGin/DNA vs BCGin, BCGsc, DNA-HSP65 and BCGsc/DNA. 
(B)  all immunized-mice vs Infected. * BCGin/DNA vs BCGsc, BCGin, DNA-HSP65 and BCGsc/DNA. (C)  BCGin, DNA-
HSP65, BCGin/DNA and BCGsc/DNA vs Infected. * BCGin/DNA vs BCGsc, DNA-HSP65 and BCGsc/DNA. (D)  BCGin, 
DNA-HSP65 and BCGin/DNA vs Infected. * BCGin/DNA vs BCGsc, DNA-HSP65 and BCGsc/DNA. # BCGin vs BCGsc. (E) 
 BCGsc, DNA-HSP65, BCGin/DNA and BCGsc/DNA vs Infected. * BCGin/DNA vs BCGsc, BCGin and DNA-HSP65. (F)  
BCGin, DNA-HSP65, BCGin/DNA and BCGsc/DNA vs Infected.* BCGin/DNA vs BCGsc, BCGin, DNA-HSP65 and BCGsc/
DNA. p < 0.05 was considered significant. Data are representative of two experiments.
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from those of BCGsc, BCGin and DNA-HSP65 groups
(Fig. 3C). We also observed significant production of
TNF-α in the lungs of BCGsc (506 ± 145 pg/mL), BCGin
(548 ± 111 pg/mL), DNA-HSP65 (461 ± 85 pg/mL),
BCGin/DNA (600 ± 51 pg/mL) and BCGsc/DNA (510 ±
76 pg/mL) groups. TNF-α secretion was very similar
among the different groups of immunized mice (Fig. 3D).
For BCGin/DNA immunized, infected mice and infected
group, we established an inverse correlation between the
levels of IFN-γ in the lungs and the numbers of CFU (Fig.
3E). Surprisingly, we observed a positive correlation
between the levels of IFN-γ and IL-10 produced in the
lung homogenates. This correlation was higher in the
lungs of BCGin/DNA mice and lower in those of infected
mice (Fig. 3F). Interestingly, the levels of IFN-γ were four
times higher than the levels of IL-10.
When we analyzed the cytokine production in all immu-
nized mice that were challenged 60 days after the last
immunization, we verified that only BCGin and BCGin/
DNA immunized, infected mice produced significant lev-
els of IFN-γ in relation to infected group on days 30 and
70 post-infection (Table 2). Notably, the levels of IFN-γ
produced by these two groups were significantly different
from those of BCGsc immunized, infected mice after 30
and 70 days of infection and only BCGin/DNA presented
significant IFN-γ production in relation to DNA-HSP65
group (Table 2). Similar results were observed when we
analyzed the production of IL-12 (Table 2). On the other
hand, we verified that all immunized, infected mice dis-
played significant production of IL-10 compared with
infected group on days 30 and 70 post-infection (Table 2).
Differently, only BCGin/DNA immunized, infected mice
presented significant IL-10 production in relation to
BCGsc, BCGin and DNA-HSP65 groups, on days 30 and
70 after infection (Table 2).
BCGin/DNA induces up-regulation of CD44hi/CD62Llo 
expression in pulmonary T lymphocytes
Two lymphocyte populations were evaluated regarding
the expression of CD44 and CD62L. With this in mind,
we intended to study lung activated/memory cells. Firstly,
we verified that all immunized, infected mice, with the
exception of BCGin group, exhibited a significant CD4+
cells influx into lungs when compared with infected mice
(Fig. 4A). However, we did not observe significant differ-
ences among the groups (Fig. 4A). On the other hand,
only BCGin/DNA-immunized, infected mice presented a
significant influx of CD8+ cells not only when compared
with infected mice but also when compared with BCGsc,
BCGin and DNA-HSP65 groups (Fig. 4A). When we ana-
lyzed the expression of CD44lo and CD62Lhi molecules on
CD4+ lymphocytes, we found variations in the percentage
of expression among all immunized-infected groups. In
comparison with the infected group, all immunized,
infected mice presented higher expression of these mole-
cules on CD4+ cells (Fig. 4C). Moreover, BCGin/DNA
group presented significant expression in relation to other
groups (Fig. 4C). We also observed that the expression of
CD44lo and CD62Lhi molecules on CD8+lymphocytes was
similar among all immunized, infected mice (Fig. 4C). We
verified that BCGin/DNA and BCGsc/DNA groups pre-
sented significant expression of CD44hi and CD62Llo on
CD4+ cells when compared with infected group (Fig. 4D).
Moreover, BCGin/DNA group also presented significant
expression of CD44hi and CD62Llo on CD4+ cells in rela-
tion to BCGsc, BCGin, DNA-HSP65 and BCGsc/DNA
groups (Fig. 4D). On top of that, only BCGin/DNA group
presented significant expression of CD44hiCD62Llo mole-
cules on CD8+ cells in relation to infected mice (Fig. 4D).
We also evaluated these cell populations 30 and 70 days
after mycobacterial infection. Thirty days after infection
we verified a significant CD4+ cells influx into lungs in all
immunized, infected mice when compared with non-
immunized infected mice and non-infected mice (Table
3). In contrast, only BCGin/DNA group presented a signif-
icant influx of CD4+ cells after 70 days of infection (Table
3). Analysis of CD8+ cells influx into lungs revealed that
all immunized, infected mice presented a significant
influx of CD8+ cells in relation to infected mice 30 days
post-infection (Table 3). When we analyzed the percent-
age of CD4+ or CD8+ cells expressing CD44hiCD62Llo 30
or 70 days post-infection, we verified that only BCGin/
DNA group presented significant expression of
CD44hiCD62Llomolecules on CD4+ cells in relation to
BCGsc, DNA-HSP65 and infected mice 70 days post-infec-
tion (Table 3). Besides, BCGin/DNA immunized, infected
mice also presented significant expression of
CD44hiCD62Llo on CD8+ cells when compared with
BCGin group 30 days post-infection (Table 3). On the
other hand, 70 days after infection BCGin/DNA group
exhibited a significant expression of these molecules on
CD8+ cells in relation to other groups: infected mice,
BCGsc, BCGin and DNA-HSP65 immunized, infected
mice (Table 3). The expression of CD44loand CD62Lhi was
also analyzed in the same cell population. Thirty days
after infection, we observed that all immunized mice pre-
sented significant percentage of CD4+ cells expressing
CD44loCD62Lhi molecules in relation to infected mice
(Table 3). This expression was significant when we com-
pared the BCGin/DNA group with BCGsc, BCGin and
DNA-HSP65 immunized, infected mice (Table 3). Equiv-
alent analyses performed 70 days post-infection revealed
that only BCGin and BCGin/DNA groups presented sig-
nificant expression of CD44loCD62Lhi on CD4+ cells com-
pared with infected group (Table 3). We also observed
that BCGin and BCGin/DNA groups presented significant
expression of CD44loCD62Lhi on CD8+ cells in relation to
infected mice 30 days after infection (Table 3). Neverthe-
less, only BCGin/DNA group presented significant expres-
Genetic Vaccines and Therapy 2007, 5:7 http://www.gvt-journal.com/content/5/1/7
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IFN-gamma, IL-12, IL-10 and TNF-alpha in lung homogenates from immunized, infected mice and infected mice after 30 days of the infectionFigur  3
IFN-gamma, IL-12, IL-10 and TNF-alpha in lung homogenates from immunized, infected mice and infected mice after 30 days of 
the infection. (A) IFN-gamma; (B) IL-12; (C) IL-10 and (D) TNF-alpha. (E) Correlation between CFU numbers and IFN-gamma 
production (F) Correlation between IFN-gamma and IL-10 production. Groups of 7 mice were immunized according table I 
and 15 days after the last immunization, they were challenged with H37Rv. After 30 days of infection, the lungs were removed 
and the cytokine production in lungs homogenates was analyzed. Bars represent the mean ± standard deviation. (A)  BCGsc, 
BCGin, DNA-HSP65, BCGin/DNA and BCGsc/DNA vs Infected mice. * BCGin/DNA vs BCGsc, BCGin, and DNA-HSP65. (B) 
 All immunized-infected mice vs Infected mice. * BCGin/DNA vs BCGsc, BCGin, DNA-HSP65 and BCGsc/DNA. ● BCGin 
vs BCGsc. (C)  All immunized-infected mice vs Infected mice. * BCGin/DNA vs BCGsc, BCGin, DNA-HSP65. (D)  All 
immunized-infected mice vs Infected mice. p < 0.05 was considered significant. Data are representative of two experiments.
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sion of CD44loCD62Lhi molecules on CD8+ cells after 70
days of infection.
Reduction of lung injury after BCGin/DNA vaccination
Histological sections of control mice are presented in 4
small pictures above the main figure (Fig. 5). Infected
mice presented extensive damage in the pulmonary
parenchyma, characterized by confluent granulomas. An
exacerbation of pulmonary infection, with a more severe
alveolar injury was observed 70 days after infection (Fig.
5, small). Lungs of non-infected mice presented a normal
alveolar architecture (Fig. 5, small).
Thirty days after infection the lungs of BCGin immunized
mice presented few granulomas with mild parenchyma
injury. After 70 days of infection, this group was character-
ized by a more extensive inflammatory response (Fig. 5X).
In the lungs of BCGsc mice, we observed sparse, well-
defined granulomas, containing macrophages and sur-
rounded by a few lymphocytic foci. These mice presented
less parenchymal damage than did infected mice, but on
day 70 after infection the granulomatous process was
more intense than that observed on day 30 post-infection
(Fig. 5C). In the BCGin/DNA group, the lung parenchyma
presented less damage and smaller foci of mononuclear
inflammatory infiltrates than in any other group. This
infiltration was characterized by the presence of macro-
phages and few lymphocytes, as well as by rare granulo-
matous lesions. Similar characteristics were observed 70
days after infection (Fig. 5D). The lungs of DNA-HSP65
immunized mice presented compact granulomas with
mild parenchyma damage after 30 days of infection. Con-
versely, on day 70 post-infection, an intense inflamma-
tory reaction characterized by the presence of multiples
granulomas and increased tecidual damage was observed
(Fig. 5X). It is noteworthy that both groups receiving
BCGin prime (BCGin/DNA, Fig. 5) presented less paren-
chymal injury than did those receiving BCGsc prime (Fig.
5X).
Discussion
In this study, we showed that heterologous prime-boost
vaccination using intranasal BCG priming/DNA-HSP65
boosting (BCGin/DNA) provided significantly greater
protection than that afforded by a single subcutaneous or
intranasal dose of BCG. In addition, BCGin/DNA immu-
nization was also more efficient in controlling bacterial
loads when compared with the other prime-boost sched-
ules (data not shown) evaluated or three doses of DNA-
HSP65 as a naked DNA. The DNA-HSP65 booster
enhanced the immunogenicity of a single subcutaneous
BCG vaccination, as evidenced by the significantly higher
serum levels of anti-Hsp65 IgG2a Th1-induced antibod-
ies, as well as by the significantly greater production of
IFN-γ by antigen-specific spleen cells. The BCGin prime
was also associated with better preservation of lung paren-
chyma. Our findings also suggest that the order of stimuli
is more relevant to the modulation of immune responses
after challenge than is the route of BCG administration.
Despite the fact that BCGin/DNA immunization clearly
induced greater protection than did BCGsc/DNA immuni-
zation, both stimulated similar levels of IFN-γ production.
Table 2: Cytokine production in lung homogenates after 30 and 70 days of challenge
Cytokines time after 
challenge
non-infected 
mice
infected mice immunized with (below) and infected with H37Rv
BCGsc BCGin DNA-HSP65 BCGin/DNA
IFN-γ (pg/mL) 30 days 692 ± 155 1069 ± 170 890 ± 87 1436 ± 185, ● 1332 ± 138 2343 ± 397, *
70 days 634 ± 110 795 ± 98 866 ± 87 1473 ± 120, ● 906 ± 64 1753 ± 190, *
IL-12 (pg/mL) 30 days 606 ± 111 1281 ± 146 1378 ± 213 1990 ± 310, ● 1624 ± 254 3476 ± 375, *
70 days 447 ± 131 926 ± 56 1090 ± 153 1562 ± 180, ● 1192 ± 186 2709 ± 322, *
IL-10 (pg/mL) 30 days 42 ± 9 104 ± 18 430 ± 23 625 ± 79, ● 558 ± 25 684 ± 104, *
70 days 30 ± 9 84 ± 4 391 ± 58 407 ± 33 334 ± 14 572 ± 46, *
TNF-α (pg/
mL)
30 days 178 ± 41 328 ± 25 505 ± 39 506 ± 58 470 ± 45 662 ± 65, *
70 days 181 ± 43 388 ± 25 530 ± 22 574 ± 44 523 ± 58 710 ± 52, *
Results were determined by ELISA in lung homogenates 30 or 70 days after infection. Mice were immunized as described in table I and 60 days after 
the last immunization they were challenged with M. tuberculosis. 30 days: (IFN-gamma):  BCGin and BCGin/DNA vs Infected mice. ●  BCGin vs 
BCGsc. * BCGin/DNA vs BCGsc, BCGin and DNA-HSP65/(IL-12):  BCGin and BCGin/DNA vs Infected mice. ●  BCGin vs BCGsc. * BCGin/
DNA vs BCGsc, BCGin and DNA-HSP65/(IL-10):  All immunized-infected mice vs Infected mice. ●  BCGin vs BCGsc. * BCGin/DNA vs BCGsc, 
BCGin and DNA-HSP65/(TNF-alpha):  All immunized-infected mice vc Infected mice. * BCGin/DNA vs BCGsc, BCGin and DNA-HSP65. 70 
days: (IFN-gamma):  BCGin and BCGin/DNA vs Infected mice. ●  BCGin vs BCGsc. * BCGin/DNA vs BCGin and DNA-HSP65./(IL-12):  BCGin 
and BCGin/DNA vs Infected mice. ●  BCGin vs BCGsc. * BCGin/DNA vs BCGsc, BCGin and DNA-HSP65/(IL-10):  All immunized-infect mice vs 
Infected mice. * BCGin/DNA vs BCGsc, BCGin and DNA-HSP65/(TNF-alpha):  All immunized-infected mice vs Infected mice. * BCGin/DNA vs 
BCGsc, BCGin and DNA-HSP65.
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Distinct prime-boost vaccination protocols have been
evaluated in experimental TB models. Goonetilleke et al.
reported that parenteral or intranasal BCG immunization
induced comparable levels of antigen-specific CD4+
responses in the spleen [11]. However, only intranasal
BCG (BCGin) elicited specific T cell responses in the
lungs. We demonstrated that, although parenteral and
intranasal prime induced comparable IFN-γ levels at the
site of the infection, the latter clearly decreased the bacte-
rial load on the order of 3 log10, in relation to non-immu-
nized, infected mice, and did not provoke lung injury
when the challenge was performed 15 days after immuni-
zation schedules. A difference of 1,2 LOG10 between the
same groups was verified when the challenge was per-
formed 60 days after vaccination. In a similar prime-boost
strategy, Mollenkopf et al. showed that a DNA vaccine
improved the efficacy of intravenous BCG prime [15].
Likewise, our results reinforce the hypothesis that a DNA
booster can increase BCG immunogenicity. Notably, in
our study, a single booster with DNA-HSP65 conferred
considerable protection. Two main aspects merit empha-
sis. The first is that intranasal route employed in our study
is less invasive, primes the lymphoid tissues (in the nasal
and bronchial mucosa) and is easily applied in humans
[16]. The second is that, in addition to increasing BCG-
related protection, prime-boost immunization also makes
it possible to optimize DNA-HSP65 immunization. In a
classical protocol of DNA vaccination, we employed a
schedule of 3 or 4 doses at 15-day intervals. In previous
studies, the protective efficacy of DNA vaccine has been
demonstrated [2,4,5,17]. Nevertheless, other authors
have found that administration of a DNA vaccine pro-
vokes a pronounced, disorganized granulomatous
response that leads to consolidation of lung tissues, and
that there was no evident protection, whether the vaccine
was used prophylactically or therapeutically [18]. In an
attempt to increase the protective effect and to minimize
possible side effects of DNA-HSP65 vaccine, we included
the BCGin/DNA prime-boost strategy in our study. This
strategy exceeded our expectations when the perspectives
described above were attended by a single DNA adminis-
tration.
To understand the possible mechanisms involved in the
up-modulation of the immune response, we sought and
found a correlation between IFN-γ and IL-10 levels, as
well as between IFN-γ levels and CFU numbers. Measur-
ing IFN-γ production by antigen-specific T cells provides
the best available immunological correlate of protection
against TB [19]. Although this immunological parameter
of protection is currently in question [20], the results
described here show that levels of "ex vivo" IFN-γ are
closely associated with protection. Surprisingly, in the
lungs of sham-immunized, infected mice and BCGin/
DNA immunized mice, we found a positive correlation
between IFN-γ and IL-10 levels after challenge and, as
expected, a negative correlation between IFN-γ levels and
CFU counts. In the lungs of BCGin/DNA mice, IFN-γ lev-
els were approximately four times higher than those of IL-
10, although IL-10 production was higher than in the
lungs of sham-immunized, infected mice. There is little
consensus in the literature regarding the role of IL-10 in
mycobacterial infection. Absence of IL-10 in the early
phase of infection favors increased resistance to mycobac-
teria [21]. However, in IL-10 transgenic murine model,
the presence of excess IL-10 did not inhibit the T cell
response to mycobacteria infection. Thus, IL-10, which
was initially found to be an inhibitor of IFN-γ secretion,
had little effect on IFN-γ production in this experimental
model. In addition, the IL-10 secreted from activated T
cells appears to have little influence on the overall pat-
terns of cytokine secretion in response to mycobacterial
CD4+/CD8+ cell numbers and expression of CD44hiCD62Llo or CD44lo/CD62Lhi in the lungs of mice fr m the various experimental groupsFigu e 
CD4+/CD8+ cell numbers and expression of CD44hiCD62Llo 
or CD44lo/CD62Lhi in the lungs of mice from the various 
experimental groups. (A) CD4+/CD8+ cell numbers in the 
lungs. (B) Representative cell gating data showing the separa-
tion of effector cell populations. (C) CD44lo/CD62Lhi expres-
sion on CD4+ and CD8+ lung cells. (D) CD44hi/CD62Llo 
expression on CD4+ and CD8+ lung cells. Groups of 7 mice 
were immunized according table I and 15 days after the last 
immunization, they were challenged with H37Rv. After 30 
days of infection, the lungs were removed and analyzed by 
flow cytometry for cell population and expression of cell sur-
face molecules. (A)  All immunized-infected mice vs 
Infected mice. * BCGin/DNA vs BCGsc, BCGin and DNA-
HSP65. (C)  All immunized-infected mice vs Infected mice. 
* BCGin/DNA vs BCGin, BCGsc and DNA-HSP65.** BCGin/
DNA vs BCGin. (D)  All immunized-infected mice vs 
Infected mice. * BCGin/DNA vs BCGsc, BCGin, DNA-
HSP65 and BCGsc/DNA. ** BCGin/DNA vs BCGsc. Bars 
represent the mean ± standard deviation. p < 0.05 was con-
sidered significant. Data are representative of two experi-
ments.
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infection [22]. In a more recent study, Jung, 2003 demon-
strated that there was no difference between wild-type and
IL-10 knockout mice in their ability to deal with mycobac-
terial infection [23]. It seems reasonable to assume that
the IFN-γ-mediated protection observed in our study was
associated with the decreased bacterial load and, conse-
quently, control of the infection, whereas the IL-10-medi-
ated protection was, to a great extent, due to an anti-
inflammatory effect related to protection against tissue
damage. Since the bacterial clearance is followed by tissue
repair, the two events are not mutually exclusive. How-
ever, the anti-inflammatory effect cannot be exclusively
attributed to IL-10. The BCGin and BCGsc mice, despite
presenting IL-10 levels that were statistically lower than
those detected in mice in the other prime-boost immu-
nized groups, also presented less parenchymal damage
than did the sham-immunized mice. In this context, it is
possible that an effector function is performed by soluble
mediators, such as transforming growth factor-β, or by
cell-cell contact mediated by regulatory T cells, although
this has yet to be investigated. It is also of note that TNF-
α levels were comparable among the various experimental
groups. Since one of the strongest correlates of TNF-α-
mediated protection is its role in granuloma formation
[24], we expected to find differences among the groups.
Although the numbers of CD8+ cells in the lungs were sig-
nificantly higher in BCGin/DNA immunized mice, TNF-α
levels were comparable among the groups, despite varia-
tions in cell number and cell constitution. These data
should motivate a search for differential cytokines, chem-
okines and adhesion receptors that might prove to be
markers of disease progression.
We also analyzed the effector/memory phenotype of T
lymphocytes in the lungs. It is well known that effector
cells express CD62Llo and CD44hi and are characteristi-
cally short-lived [25]. We have previously shown that
expression of CD44hi on CD4+ and CD8+ cells is related to
protection against TB [2,6]. However, Kipnis et al. recently
reported that the transference of spleen cells expressing a
resting/naïve phenotype (CD62Lhi/CD44lo) but not effec-
tor cells (CD62Llo/CD44hi) protected the recipients after
challenge with M. tuberculosis [26]. The authors suggested
that the emergence of T cell memory from the naive subset
induces IFN-γ-mediated protection. We found an increase
of CD4+ and CD8+ populations that express
CD44hiCD62Llo in the lungs of BCGin/DNA, however we
did not find striking differences in the CD44loCD62Lhi
populations among the distinct groups of immunized,
infected mice.
Table 3: CD4+/CD8+ cell numbers and expression of CD44hiCD62Llo or CD44lo/CD62Lhi in the lungs of mice
time after 
challenge
non-infected 
mice
infected mice immunized with (below) and infected with H37Rv
BCGsc BCGin DNA-HSP65 BCGin/DNA
CD4+ 30 days
70 days
2.4 ± 0,6
1 ± 0,1
5 ± 0,8
1,6 ± 0,2
9 ± 0,7
1,7 ± 0,6
10,2 ± 0,5
2,18 ± 0,7
10,2 ± 0,8
1,64 ± 0,1
12,8 ± 1,5, *
2,8 ± 0,5, *
CD8+ 30 days 1,4 ± 0,2 2,5 ± 0,06 4,5 ± 0,4 5,9 ± 0,6 4,7 ± 1,5 6,2 ± 1,5
70 days 0,6 ± 0,3 1 ± 0,3 1 ± 0,4 1,3 ± 0,3 1 ± 0,1 1,4 ± 0,2
CD4+/CD44hi/
CD62Llo
30 days 6,1 ± 2 12,8 ± 2,6 10 ± 4,7 10,7 ± 2,5 11,8 ± 2 15,3 ± 4
70 days 1,5 ± 0,5 3,6 ± 0,9 4,5 ± 1,4 6 ± 1 3,4 ± 0,9 9 ± 2,2, *
CD8+/CD44hi/
CD62Llo
30 days 7,2 ± 1,4 14,6 ± 3,1 14,8 ± 6,4 12,8 ± 4 14,5 ± 1,3 20,8 ± 0,6*
70 days 1 ± 0,3 2,5 ± 0,7 2 ± 0,8 2,2 ± 1,7 2,7 ± 0,3 5,2 ± 0,5, *
CD4+CD44lo/
CD62Lhi
30 days 14 ± 1,5 17 ± 1,42 19,5 ± 2,6 36,8 ± 5,4, ● 24,6 ± 2,5 35,6 ± 4,3, *
70 days 12 ± 2,4 22,2 ± 1,27 26,2 ± 7,5 37,5 ± 5, ● 30 ± 3,8 42,4 ± 5,4, *
CD8+CD44lo/
CD62Lhi
30 days 15,3 ± 2 19,38 ± 1,7 21,9 ± 4,1 29 ± 2,8 18,42 ± 5,6 41,2 ± 6,5, *
70 days 8,7 ± 2 16 ± 4,4 24,3 ± 7,1 22,6 ± 1,1, ● 27,45 ± 6,1 35,2 ± 7,3, *
Results were determined by flow cytometry. Number of CD4+ and CD8+ × 106 cells/mL. Expression of CD44hi/CD62Llo or CD44lo/CD62Lhi by 
CD4+ or CD8+ cells was calculated in percentage from dot plots analysis. Mice were immunized as described in table I and 60 days after the last 
immunization they were challenged with M. tuberculosis. 30 days: (CD4):  All immunized-infected mice vs Infected mice. * BCGin/DNA vs BCGsc, 
BCGin and DNA-HSP65/(CD8):  All immunized-infected mice vs Infected mice/(CD8+CD44hiCD62Llo): * BCGin/DNA vs BCGin/
(CD4+CD44loCD62Lhi):  All immunized-infected mice vs Infected mice. ●  BCGin vs BCGsc. * BCGin/DNA vs BCGsc, DNA-HSP65/
(CD8+CD44loCD62Lhi):  BCGin and BCGin/DNA vs Infected mice. * BCGin/DNA vs BCGsc, BCGin and DNA-HSP65. 70 days: (CD4):  
BCGin/DNA vs Infected mice. * BCGin/DNA vs BCGsc and DNA-HSP65/(CD4+CD44hiCD62Llo):  BCGin/DNA vs Infected mice. * BCGin/DNA 
vs BCGsc, BCGin and DNA-HSP65/(CD8+CD44hiCD62Llo):  BCGin/DNA vs Infected mice. * BCGin/DNA vs BCGsc, BCGin and DNA-HSP65/
(CD4+CD44loCD62Lhi):  BCGin and BCGin/DNA vs Infected mice. ●  BCGin vs BCGsc. * BCGin/DNA vs BCGsc and DNA-HSP65./
(CD8+CD44loCD62Lhi):  BCGin/DNA and BCGin vs Infected mice. ●  BCGin vs BCGsc. * BCGin/DNA vs BCGsc, DNA-HSP65.
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Profile of the inflammatory infiltrates in lungs of mice that were immunized, as described in table I and infected with H37Rv (105 bacilli/mouse) by int atrache l routeFigure 5
Profile of the inflammatory infiltrates in lungs of mice that were immunized, as described in table I and infected with H37Rv 
(105 bacilli/mouse) by intratracheal route. Thirty and 70 days after infection, the lungs were removed and the histological anal-
ysis were performed in H.E. staining. Small pictures represent the controls (infected and non-infected mice). The main figure 
shows all immunized, infected mice as observed in the individual description per figure. The left column represent 30 days and 
the right one represent 70 days after infection. Original magnification: 40×.
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In conclusion, we found that a DNA-HSP65 booster
increased BCG-mediated protection and that the order of
stimulation was a relevant correlate for this protection.
This makes the BCGin/DNA strategy attractive because it
does not preclude childhood BCG vaccination. Increased
protective efficacy induced by the DNA-HSP65 booster
appeared to be attributable to increased numbers of CD4+
and CD8+ cells expressing the effector phenotype
CD62Llo/CD44hi, as well as to higher IFN-γ, IL-10 and IL-
12 levels.
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